Clinical Trial Update: Safety, Immunogenicity and Efficacy of R21 Matrix-M in 5-17 Month Old Children in Nanoro, Burkina Faso [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 trial in 5-17 month old children in Nanoro, Burkina Faso evaluated the safety, immunogenicity, and efficacy of the R21 Matrix-M malaria va…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malaria
• Plasmodium Falciparum Malaria

Drugs mentioned

• R21/Matrix-M malaria vaccine (R21/Matrix-M malaria vaccine)

Snippet

Sponsor: University of Oxford | Conditions: Malaria,Falciparum | Phase 1, Phase 2 | Status: COMPLETED